Literature DB >> 2571972

Pharmacology of new hormonal therapies in the treatment of pediatric endocrine disorders.

A L Usala1, J L Blumer.   

Abstract

Advances in genetic engineering will make possible treatment of many pediatric endocrine disorders with replacement therapy. Some of these conditions include short stature, precocious puberty, and diabetes mellitus. Although the availability of such hormonal replacement offers new treatment modalities, an understanding of their mechanism of action and pharmacologic characteristics is crucial to maximize their effectiveness while minimizing possible untoward effects. The clinician must evaluate potential risks and benefits as these substances come to market without definitive answers being available as to their long-term effects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571972     DOI: 10.1016/s0031-3955(16)36763-3

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  1 in total

1.  The level of bioavailable growth hormone (GH) after the first GH injection predicts the first year's growth response in GH-deficient children.

Authors:  M Bozzola; G Radetti; S Pagani; M Draghi; G Aimaretti; G Rondini
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.